SRF SRF Q3 FY26 results (Oct–Dec 2025) and concall
SRF reported a healthy Q3 FY26 with 6% revenue growth and 60% PAT expansion, primarily driven by strong performance in the Fluorochemicals segment. However, Specialty Chemicals and Performance Films faced headwinds from Chinese competition, pricing pressure, and demand deferrals. The company is strategically investing in new generation gases and expanding its pharma intermediate capacity to diversify its portfolio and mitigate risks.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 6.9%, net profit up 63.6% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,762 | 3,496 | 3,040 | 2,853 | 2,952 +7% |
| EBITDA | 557 | 876 | 724 | 675 | 743 +33% |
| Net profit | 280 | 513 | 397 | 363 | 458 +64% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
